EIC Accelerator

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Premium Fertility develops an assisted reproductive technology for embryo transfer, featuring a direct embryo transfer system that integrates optical, microfluidic, and automated components to enable clinicians to place embryos with greater precision and consistency while addressing uncertainties in attachment.

NextKidney is a medical device company that specializes in the development of portable and cost-effective solutions for hemodialysis treatment. Its flagship product, Neokidney, empowers patients by enabling them to perform dialysis at home or on the go, thereby restoring their autonomy and freedom. The Neokidney device is compact enough to fit on a nightstand, minimizing its intrusiveness in personal living spaces. Unlike traditional dialysis systems, which require large fluid volumes, Neokidney utilizes a sorbent cartridge to regenerate dialysis fluid, needing only 5 liters of fluid in bags. This innovative approach simplifies the logistics of dialysis, allowing patients to maintain their social and professional lives without the burden of extensive infrastructure or fluid management.

IXI is a company focused on advancing optical eyeglasses technology to enhance vision. It specializes in innovative lenses designed to offer a wide and clear field of view for both near and intermediate distances, effectively addressing the shortcomings of conventional progressive lenses. By providing a farsighted eyeglass prescription, IXI enables users to read and work with optimal vision without the need for multifocal lenses or constant switching of eyeglasses. The company aims to modernize traditional eyeglass optics, ensuring that individuals can experience vision as nature intended.

Premium Fertility develops an assisted reproductive technology for embryo transfer, featuring a direct embryo transfer system that integrates optical, microfluidic, and automated components to enable clinicians to place embryos with greater precision and consistency while addressing uncertainties in attachment.

Developer of a revolutionary thrombectomy device designed specifically for treating ischemic stroke. The company's innovative technology enables efficient and safe removal of blood clots from large to small vessels, even in distal regions of the brain, improving patient outcomes.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

StarTric develops a minimally invasive device for treating tricuspid regurgitation, a common cause of heart failure. Their transcatheter repair implant reduces blood flow to the lungs, preventing symptoms such as atrial fibrillation and improving patient outcomes.

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

IXI is a company focused on advancing optical eyeglasses technology to enhance vision. It specializes in innovative lenses designed to offer a wide and clear field of view for both near and intermediate distances, effectively addressing the shortcomings of conventional progressive lenses. By providing a farsighted eyeglass prescription, IXI enables users to read and work with optimal vision without the need for multifocal lenses or constant switching of eyeglasses. The company aims to modernize traditional eyeglass optics, ensuring that individuals can experience vision as nature intended.

Developer of a revolutionary thrombectomy device designed specifically for treating ischemic stroke. The company's innovative technology enables efficient and safe removal of blood clots from large to small vessels, even in distal regions of the brain, improving patient outcomes.

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

NextKidney is a medical device company that specializes in the development of portable and cost-effective solutions for hemodialysis treatment. Its flagship product, Neokidney, empowers patients by enabling them to perform dialysis at home or on the go, thereby restoring their autonomy and freedom. The Neokidney device is compact enough to fit on a nightstand, minimizing its intrusiveness in personal living spaces. Unlike traditional dialysis systems, which require large fluid volumes, Neokidney utilizes a sorbent cartridge to regenerate dialysis fluid, needing only 5 liters of fluid in bags. This innovative approach simplifies the logistics of dialysis, allowing patients to maintain their social and professional lives without the burden of extensive infrastructure or fluid management.

StarTric develops a minimally invasive device for treating tricuspid regurgitation, a common cause of heart failure. Their transcatheter repair implant reduces blood flow to the lungs, preventing symptoms such as atrial fibrillation and improving patient outcomes.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

MindPeak GmbH is a technology company based in Hamburg, Germany, founded in 2018. It specializes in developing artificial intelligence software tools aimed at enhancing the accuracy and efficiency of cancer diagnostics. The company's flagship product, BreastAI, is designed for the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. MindPeak's solutions automate tissue diagnostics, enabling pathologists to identify and quantify tumorous regions and detect breast cancer cells more effectively. By streamlining tasks such as cell and biomarker quantification, MindPeak's tools allow cancer specialists to focus on critical decision-making in clinical environments, ultimately improving patient care while making diagnostic processes more accessible and cost-effective.

Omini develops a portable, multiplex biosensor platform for blood testing that enables the simultaneous detection of multiple biomarkers. The device is designed for chronic disease monitoring and therapy management, providing personalized biomarker data to adjust treatments and help prevent acute crises, with applications for general practitioners. Incorporated in 2019 and based in Saint-Mandé, France, Omini aims to offer a low-cost, regular monitoring solution that supports routine assessment of complex conditions such as heart failure.

Diamante is a company based in Verona, Italy, that specializes in the development and manufacturing of diagnostic devices for autoimmune diseases, utilizing innovative nanomaterials. Founded in 2016, the company leverages plants as bioreactors to produce nanoparticles derived from modified plant viruses. This approach allows Diamante to create advanced tools for diagnosing and potentially treating autoimmune conditions, focusing on sustainable and efficient production methods. Through its research and development efforts, Diamante aims to contribute significantly to the field of autoimmune disease therapy.

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

JaxBio develops AI-driven diagnostic technology for cancer, using AI-based chips for genetic and epigenetic profiling and array-based cancer tests to enable a simple, sensitive blood test for cancer detection and monitoring. Its technology identifies biomarker sets that distinguish cancer types and subtypes across stages, supporting early detection, disease monitoring, and prediction of treatment response.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Multi4 Medical specializes in developing automated endoscopic technologies for cancer diagnosis and treatment. Their patented technique aims to reduce patient discomfort, accelerate recovery, and lower healthcare costs by enabling procedures in outpatient settings.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Omini develops a portable, multiplex biosensor platform for blood testing that enables the simultaneous detection of multiple biomarkers. The device is designed for chronic disease monitoring and therapy management, providing personalized biomarker data to adjust treatments and help prevent acute crises, with applications for general practitioners. Incorporated in 2019 and based in Saint-Mandé, France, Omini aims to offer a low-cost, regular monitoring solution that supports routine assessment of complex conditions such as heart failure.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

Diamante is a company based in Verona, Italy, that specializes in the development and manufacturing of diagnostic devices for autoimmune diseases, utilizing innovative nanomaterials. Founded in 2016, the company leverages plants as bioreactors to produce nanoparticles derived from modified plant viruses. This approach allows Diamante to create advanced tools for diagnosing and potentially treating autoimmune conditions, focusing on sustainable and efficient production methods. Through its research and development efforts, Diamante aims to contribute significantly to the field of autoimmune disease therapy.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

neuroClues develops AI-driven eye-tracking technology for clinical use that quantifies neurological function during exams. The platform provides an easy-to-use eye-tracking environment enabling clinicians to assess brain health non-invasively and monitor neurological conditions. By applying AI to eye movement data, the company aims to enable earlier detection of neurological disorders such as Parkinson's and Alzheimer's disease, potentially improving patient outcomes and informing treatment decisions. The approach offers a non-invasive diagnostic aid that can complement traditional assessments and support streamlined clinical workflows.

Medicsen is a start-up focused on healthcare innovation, primarily through the development of advanced technology solutions. A notable project is GlycSen, a needle-free drug delivery device aimed at providing a painless treatment option for individuals with insulin-dependent diabetes. This device integrates data from continuous glucose meters and user-inputted information, utilizing a learning algorithm to facilitate real-time monitoring. It features a chatbot interface that allows patients to easily track their condition, enhancing their ability to manage diabetes effectively. Through these innovations, Medicsen aims to improve the quality of life for those living with chronic diseases.

DoMore Diagnostics is dedicated to transforming cancer diagnostics through the use of artificial intelligence. The company focuses on developing advanced diagnostic technology that enhances the accuracy of cancer assessments. By predicting the progression of cancer in patients and forecasting potential outcomes, DoMore Diagnostics aims to improve patient care significantly. Their innovative approach not only facilitates tailored treatment options for patients but also enhances the overall efficiency of drug development processes.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

O11 Biomedical GmbH is a spin-off from RWTH Aachen University's Institute for Applied Medical Engineering, specifically the Department of Biohybrids & Medical Textiles. The company specializes in liquid breathing technology aimed at treating hypercapnia, a condition characterized by elevated carbon dioxide levels in the blood. O11 Biomedical's innovative technology effectively binds carbon dioxide from intestinal fluid, facilitating its excretion through natural processes. By doing so, the company seeks to enhance both the survival and quality of life for patients afflicted with this respiratory condition.

KLISBio is a pioneering company in regenerative medicine that utilizes silk as a versatile and biocompatible scaffold material to advance tissue regeneration methods. The company focuses on various clinical applications within the orthopedic and vascular markets, developing innovative silk-based biomaterials that facilitate the regeneration of human tissues. These materials are designed to degrade safely within the body, making them suitable for medical research and treatment of tissue-related diseases. By harnessing the potential of nano-fibers, KLISBio aims to transform the landscape of medical technology and improve patient outcomes.

Delox designs and develops bio-decontamination devices and automatic decontamination robots that use a solid hydrogen peroxide formulation to deliver rapid, safe disinfection and maintain sterile conditions in healthcare, laboratory and industrial environments. Originating as a spin-off from the University of Lisbon's Faculty of Sciences, the company focuses on compact, cost-effective solutions such as the Delox Box, supported by DeloxHP cartridges that store and release concentrated hydrogen peroxide vapor. Its products enable sterilization of medical devices in hospitals, room decontamination in medical facilities, pharma and food industries, as well as decontamination of laboratory equipment and environmental test chambers. Founded in 2018 and based in Cascais, Portugal, Delox targets facilities that require non-toxic, efficient bio-decontamination to preserve biosafety and reduce downtime.

Womed SAS, founded in 2018, is a medical device company that originated from research at Professor Garric's biopolymer lab at the University of Montpellier, France. The company focuses on addressing unmet medical needs in gynecologic surgery, particularly intrauterine adhesions, which can impact fertility and pregnancy. Womed develops insertable devices designed to act as mechanical barriers against adhesions, protecting the uterine cavity. These devices are engineered to break up, dissolve, and be naturally discharged without requiring intervention from healthcare professionals, thereby helping women reduce or prevent recurrent intrauterine adhesion formation and miscarriage.

Novelrad is a privately held medical device company that specializes in innovative micro-sewing technology. The company has developed a suturing device designed for the closure of vascular and heart defects. This device allows for the deployment of various continuous suture patterns and multipoint purse string sutures, facilitating safe dilation at the start of surgical procedures and ensuring reliable closure at their conclusion. Through its advanced technology, Novelrad aims to enhance surgical outcomes and improve patient safety in cardiovascular surgeries.

BetaGlue Technologies SpA is a Milan-based company that specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product features a proprietary beta-emitting biocompatible matrix, which facilitates the controlled administration of radionuclides directly into tumor masses. This technology not only enhances the effectiveness of cancer treatment but also plays a crucial role in preventing complications that can arise following procedures such as lung and liver biopsies. By focusing on localized therapies, BetaGlue Technologies aims to improve patient outcomes and advance the field of cancer treatment.

Cephalgo is a company that specializes in mental health solutions, providing psychiatrists with innovative wearable electroencephalography equipment. This technology allows for the automatic and precise monitoring of emotions through brainwaves, facilitating remote patient tracking. Additionally, Cephalgo has developed a mood tracker platform aimed at enhancing mental health by automatically tracking mood and analyzing emotional profiles. This platform empowers users to access self-help resources and treatment planning, contributing to more effective management of mental health conditions. Through its advanced tools, Cephalgo strives to improve the quality of care in the mental health field.

Rehaler is a biomedical company developing and commercializing novel treatments for migraine with aura. Its flagship product is a drug-free inhaler that modulates oxygen levels in the inspired air, helping patients manage their migraines more effectively.

Thirona is a software company that develops AI-powered medical imaging analysis tools and provides image analysis services for the healthcare industry. Its automated tools support the analysis of thoracic CT scans, chest X-rays, and retinal images, delivering accurate and repeatable measurements to help hospitals detect and mitigate diseases. The company offers software solutions and certified image analysis services that streamline imaging workflows and improve diagnostic precision.

Better Medicine develops an AI-powered radiology platform aimed at streamlining cancer diagnostics. Its platform offers multi-organ analysis, automated lesion detection, integrated reporting tools, and compatibility with existing systems, enabling healthcare providers to enhance diagnostic accuracy and deliver personalized care.

Angiolutions develops innovative therapeutic devices focused on treating vascular diseases, notably minor abdominal aortic aneurysms. Their groundbreaking approach involves a novel vascular graft designed to halt the growth of these aneurysms.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Luminate Medical specializes in developing innovative medical devices aimed at preventing hair loss during chemotherapy. Recognizing the significant impact of hair loss on patients' self-esteem, the company focuses on utilizing advanced medical technology to protect this essential element of personality.

Nimble Diagnostics is a company that offers a range of DNA testing services, including paternity testing, prenatal gender testing, family relationship testing, ancestry DNA testing, and DNA art. In addition to these services, the company provides cancer nutraceuticals, aiming to support patients' health and well-being. Nimble Diagnostics leverages the internet to deliver its offerings globally at affordable prices, maintaining a commitment to accessible molecular diagnostics. The company also focuses on developing medical monitoring devices that enhance patient care, particularly for individuals with medical implants. These devices enable continuous, non-invasive monitoring, allowing healthcare providers to transition from reactive to proactive care, thereby reducing clinical complications associated with implanted stents.